Mumbai: Pharma Major, Glenmark Pharma on Thursday said that its US subsidiary Glenmark Pharmaceuticals Inc., USA has launched Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial.
It is used for emergency treatment of severe allergic reactions to insect
bites or stings, medicines or other substances.
At launch, Marc Kikuchi, President & Business Head, North America said, “We are excited to announce the launch of Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients.”
Glenmark’s Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL), of BPI Labs, LLC, NDA 205029, company release said
According to sales data for the 12-month period ending December 2024, the Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) market achieved annual sales of approximately $42.7 million, it added.
